Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 21;9(3):LMT32.
doi: 10.2217/lmt-2020-0004.

Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung

Rodney E Wegner  1 , Stephen Abel  1 , Athanasios Colonias  1
Affiliations

Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung

Rodney E Wegner et al. Lung Cancer Manag. .

Abstract

Aim: Some patients with early stage large cell neuroendocrine carcinoma (LCNEC) of the lung are not surgical candidates and will be managed with radiotherapy. We used the national cancer database to identify predictors of stereotactic radiotherapy and compare outcomes.

Materials & methods: We queried national cancer database for T1-2N0 LCNEC treated with radiation. Logistic regression and Cox regression identified predictors of stereotactic ablative body radiotherapy (SABR) and survival, respectively.

Results: We identified 754 patients, with 238 (32%) treated with SABR. Predictors of SABR were distance to facility, no chemotherapy, academic center, T1 and recent year. After propensity matching, median survival was 34.7 months compared with 23.7 months in favor of SABR (p = 0.02).

Conclusion: SABR for LCNEC has increased over time and was associated with improved survival.

Keywords: SABR; SBRT; large cell neuroendocrine; radiation therapy.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. CONSORT diagram showing selection criteria.
Figure 2.
Figure 2.. Propensity matched Kaplan–Meier curve showing benefit to stereotactic ablative body radiotherapy with a median overall survival 34.7 versus 23.7 months; p = 0.02.
CFRT: Conventionally fractionated radiation therapy; SABR: Stereotactic ablative body radiotherapy.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018). - PubMed
    1. Glisson BS, Moran CA. Large-cell neuroendocrine carcinoma: controversies in diagnosis and treatment. J. Natl Compr. Canc. Netw. 9(10), 1122–1129 (2011). - PubMed
    1. Timmerman R, Paulus R, Galvin J. et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11), 1070–1076 (2010). - PMC - PubMed

    2. • Landmark study on use of stereotactic ablative body radiotherapy in NSCLC.

    1. Singh R, Ansinelli H, Sharma D. et al. Clinical outcomes following stereotactic body radiation therapy (SBRT) for stage I medically inoperable small cell lung carcinoma: a multi-institutional analysis from the RSSearch patient registry. Am. J. Clin. Oncol. 42(7), 602–606 (2019). - PubMed
    1. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 45(6), 613–619 (1992). - PubMed

LinkOut - more resources